Actinium Pharma CFO to step down Feb 27

Actinium Pharmaceuticals reported a leadership change in its finance function.

Rhea-AI Filing Summary

Actinium Pharmaceuticals reported a leadership change in its finance function. Chief Financial Officer Steve O’Loughlin has resigned, effective February 27, 2026, to pursue other opportunities. The company states there were no disagreements that contributed to his decision.

To fill the principal financial officer role, the Board appointed Sandesh Seth, the current Chairman and Chief Executive Officer, effective as of the same date. Seth has led the company as CEO since 2017, has served on the Board since 2012, and brings more than 25 years of experience in investment banking, equity research, and the pharmaceutical industry. The filing notes there are no disclosable family relationships or related-party transactions involving him.

Insights

Corporate governance analyst

CFO exits while the CEO assumes finance duties, concentrating leadership roles.

Actinium Pharmaceuticals disclosed that CFO Steve O’Loughlin will resign effective February 27, 2026, and that Chairman and CEO Sandesh Seth will also serve as principal financial officer from that date. The company states there were no disagreements behind the resignation.

This move temporarily combines top executive and finance responsibilities in one individual. Seth’s long tenure with the company and his background in finance and pharmaceuticals may support continuity, but the structure reduces separation between strategic leadership and financial oversight.

The filing does not outline any further changes to the finance organization or succession plans. Future company disclosures may provide more detail on whether a dedicated CFO will be appointed or if this combined role will continue longer term.

8-K Event Classification

Item 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers

1 item

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers Governance

Key personnel changes including departures, elections, or appointments of directors and executive officers.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What leadership change did Actinium Pharmaceuticals (ATNM) announce in this 8-K?

Actinium Pharmaceuticals announced that Chief Financial Officer Steve O’Loughlin resigned effective February 27, 2026. To fill the principal financial officer role, the Board appointed Chairman and CEO Sandesh Seth to assume that responsibility starting on the same effective date.

When does Actinium Pharmaceuticals’ CFO Steve O’Loughlin officially leave his role?

Steve O’Loughlin’s resignation as Chief Financial Officer becomes effective on February 27, 2026. He notified Actinium Pharmaceuticals of his decision on February 11, 2026, giving the company time to arrange a transition in its principal financial officer responsibilities.

Did Actinium Pharmaceuticals report any disagreements related to the CFO’s resignation?

Actinium Pharmaceuticals stated there were no disagreements with the company that contributed to CFO Steve O’Loughlin’s resignation. The filing characterizes his departure as a move to pursue other opportunities, without citing disputes over operations, policies, or financial reporting.

Who will serve as principal financial officer of Actinium Pharmaceuticals (ATNM)?

The Board appointed Chairman and Chief Executive Officer Sandesh Seth to serve as Actinium Pharmaceuticals’ principal financial officer. His appointment becomes effective February 27, 2026, aligning with the effective date of CFO Steve O’Loughlin’s resignation from the company.

What is Sandesh Seth’s background at Actinium Pharmaceuticals (ATNM)?

Sandesh Seth has been Actinium Pharmaceuticals’ Chief Executive Officer since June 2017 and a Director since March 2012. He became Chairman in October 2013 and previously served as Executive Chairman, bringing extensive investment banking, equity research, and pharmaceutical industry experience.

Are there any related-party relationships or transactions involving Sandesh Seth disclosed?

The company states there are no family relationships between Sandesh Seth and any director or executive officer requiring disclosure. It also reports no transactions involving him that would need to be disclosed under Item 404(a) of Regulation S-K for related-party transactions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/13/2026 - 05:00 PM Learn about SEC filing dates

false 0001388320 DE 0001388320 2026-02-11 2026-02-11 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 11, 2026

Actinium Pharmaceuticals, Inc.

(Exact name of registrant as specified in its charter)

Delaware		001-36374		74-2963609
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

100 Park Ave., 23rd Floor,

New York, New York 10017
(Address of principal executive offices) (Zip code)

(646) 677-3870
(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 Under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		ATNM		NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

On February 11, 2026, Steve O’Loughlin tendered his resignation as the Chief Financial Officer of Actinium Pharmaceuticals, Inc. (the “Company”), effective as of February 27, 2026, to pursue other opportunities (the “Effective Date”). There were no disagreements with the Company that contributed to Mr. O’Loughlin’s resignation.

Additionally, on February 13, 2026, to fill the executive vacancy as a result of Mr. O’Loughlin’s resignation as the principal financial officer of the Company, the Board appointed Sandesh Seth, the current Chairman and Chief Executive Officer of the Company, to serve as the principal financial officer, effective as of the Effective Date.

Mr. Sandesh Seth has been the Chief Executive Officer of the Company since June 2017. Mr. Seth has been a Director since March 2012, the Company’s Chairman of the Board since October 2013, and served as Executive Chairman from August 2014 to June 2017. Mr. Seth has 25 plus years of experience in investment banking (Laidlaw& Co (UK) Ltd., Cowen & Co.), equity research (Bear Stearns, Commonwealth Associates) and in the pharma industry (Pfizer, Warner-Lambert, SmithKline in strategic planning, business development and R&D project management). Mr. Seth was chairman of Relmada Therapeutics Inc., a specialty pharma company focused on CNS therapeutics, which he helped co-found. Mr. Seth has an MBA in Finance from New York University, an M.S. in the Pharmaceutical Sciences from the University of Oklahoma Health Center and a B.Sc. in Chemistry from Bombay University. He has published several scientific articles and was awarded the University Regents Award for Research Excellence at the University of Oklahoma. Mr. Seth was designated as Regulatory Affairs Certified by the Regulatory Affairs Professionals Society which signifies proficiency with U.S. FDA regulations. He has several patents related to the use of radiopharmaceuticals as conditioning agents for adoptive cell therapies and as therapeutic combinations.

There are no family relationships between Mr. Seth and any director or executive officer of the Company that would be required to be disclosed pursuant to Item 401(d) of Regulation S-K, and there are no transactions involving Mr. Seth that would be required to be disclosed pursuant to Item 404(a) of Regulation S-K.

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ACTINIUM PHARMACEUTICALS, INC.
Date: February 13, 2026	By:	/s/ Sandesh Seth
		Name: Sandesh Seth
		Title:   Chairman and Chief Executive Officer

2

Filing Exhibits & Attachments

3 documents

Other Documents

• EX-101 XBRL SCHEMA FILE 3.0 KB
• EX-101 XBRL LABEL FILE 33.4 KB
• EX-101 XBRL PRESENTATION FILE 21.8 KB